SBC Medical Group Holdings Incorporated (SBCWW)
Valuation Overview•Is SBC Medical Group Holdings Incorporated Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
High-quality fundamentals with a strong composite quality score of 86/100, backed by robust profitability and solvency.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: High-quality compounder, with growth as the only relative weakness.
Wall Street sentiment is generally neutral. This outlook is strongly supported by highly attractive capital returns, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
SBCWW exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins (highlighted by a massive 43.4% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($112M) and minimal debt risk.
The company is facing top-line contraction (-0.1% 3Y CAGR) paired with highly explosive earnings growth (138.8% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 36.0% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $43.1M | -15.5% | -0.1% | — | — | |
| EBITDA | $18.4M | — | +39.1% | — | — | |
| Net Income | $11.3M | +9.4% | +100.6% | — | — | |
| EPS (Diluted) | $0.11 | +4.2% | +138.8% | — | — | |
| Free Cash Flow | $8.7M | -29.6% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 70.6% | 73.4% | 71.5% | 71.5% |
| Operating Margin | 36.0% | 36.5% | 30.3% | 30.3% |
| Net Margin | 24.1% | 24.1% | 19.0% | 19.0% |
| FCF Margin | 26.0% | 22.2% | 13.1% | 13.1% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.10 | $0.11 | +12.2% | ||
| Q1'26 | $0.12 | $0.14 | +17.2% | ||
| Q4'25 | $0.11 | $0.12 | +13.5% | ||
| Q3'25 | $0.14 | $0.02 | -82.4% |
Total return is -26.6% (1Y), lagging the benchmark by -51.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -17.2% | -26.5% | — |
| 1Y | -26.6% | -51.6% | — |
| 3YCAGR | +42.3% | +22.2% | — |
| 5YCAGR | +23.5% | +10.8% | — |
| 10YCAGR | +11.2% | -2.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about SBCWW (SBCWW) valuation, health, and returns.
SBCWW valuation is being assessed using available models.
Valuation anchors are currently not available.
SBCWW displays excellent financial health with a composite quality score of 86/100, supported by a Altman Z-Score of 2.4 (grey zone), Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of 43.4%.
SBCWW returns capital via buybacks instead of dividends, carrying a 26.0% buyback yield and reducing outstanding shares by +6.7% in the last 12 months.
SBCWW's current growth trajectory is Decelerating. The company achieved -15.5% 1Y revenue growth and +4.2% 1Y EPS growth, compared to its 3Y revenue CAGR of -0.1%.
Wall Street consensus is Hold based on 0 analysts, beating EPS expectations in 75% of recent quarters with a 3-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for SBCWW include: -57.6% 1-year max drawdown. Volatility risk is characterized by a beta of 1.09x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.